This multicenter, open-label extension study of Protocol 2993-112 is designed to assess
long-term glucose control as measured by HbA1c (glycosylated hemoglobin) and to evaluate
long-term safety and tolerability in subjects treated with metformin who receive
subcutaneously injected AC2993 (10 mcg) administered twice daily. Subjects completing
Protocol 2993-112 are eligible to enroll.